(APLT) – Hot FDA News
-
Applied Therapeutics (APLT) Falls 36% After ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy Fails
-
Applied Therapeutics (APLT) Provides Regulatory Update on Galactosemia Program, Says FDA Indicated Clinical Outcomes Data Will Likely be Required
-
Back to APLT Stock Lookup